Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritisReport as inadecuate

Inflammatory bowel disease following anti-interleukin-1-treatment in systemic juvenile idiopathic arthritis - Download this document for free, or read online. Document in PDF available to download.

Pediatric Rheumatology

, 15:16

First Online: 14 March 2017Received: 28 September 2016Accepted: 06 March 2017


BackgroundInflammatory bowel disease can develop in the context of some rheumatic diseases in childhood, including juvenile idiopathic arthritis JIA. Inflammatory bowel disease IBD is frequently associated with other immune-mediated diseases; however, systemic onset JIA sJIA has not previously been connected to IBD. Treatment of sJIA has significantly changed in recent years, possibly causing changes in inflammatory patterns. Therefore, data from the German Center for Pediatric and Adolescent Rheumtology from 2010 until 2015 were analyzed by retrospective chart review.

FindingsEighty-two patients with confirmed diagosis of sJIA were found. Of these, three were identified with a diagnosis of IBD confirmed by colonoscopy two cases of Crohn’s disease, one case of ulcerative colitis 0.8 – 4.3 years after diagnosis. All three were treated with IL-1 antagonists anakinra in two cases, canakinumab in one case and were well controlled for sJIA symptoms at time of diagnosis of IBD

ConclusionsIBD seems to be a rare, but possible complication of sJIA. Treatment with IL-1 antagonists might be a relevant factor for a switch in the clinical phenotype of the underlying inflammatory process.

KeywordsSystemic juvenile idiopathic arthritis Inflammatory bowel disease IL-1 Antagonists Electronic supplementary materialThe online version of this article doi:10.1186-s12969-017-0147-3 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Author: Boris Hügle - Fabian Speth - Johannes-Peter Haas


Related documents